Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
- 1 June 1978
- journal article
- Vol. 3, 281-5
Abstract
Since April 1976 we have performed clinical investigations with multiple doses of the hypoxic cell radiosensitizer misonidazole in 21 patients. A significant side effect of the drug was the development of peripheral sensory neuropathies in 13 patients (8 mild, 5 severe) and of a transient acute organic psychosyndrome in 2 of the 5 patients with a severe polyneuropathy. The severity of the polyneuropathies is related to the total dose of misonidazole and the overall time of drug administration. Treatment schedules designed to obtain the desired sensitizing effect without neurological side effects are under investigation.This publication has 9 references indexed in Scilit:
- Clinical testing of the radiosensitizer Ro 07-0582: Experience with multiple dosesBritish Journal of Cancer, 1977
- Clinical Phase I Study of the Hypoxic Cell Radiosensitizer RO-07-0582, A 2-Nitroimidazole DerivativeRadiology, 1977
- Radiosensitizers of hypoxic cells in solid tumoursCancer Treatment Reviews, 1976
- Optimum fractionation of the C3H mouse mammary carcinoma using X-rays, the hypoxic-cell radiosensitizer Ro-07-0582, or fast neutronsInternational Journal of Radiation Oncology*Biology*Physics, 1976
- Metronidazole neuropathy.Journal of Neurology, Neurosurgery & Psychiatry, 1976
- An investigation of the pharmacological and radiosensitizing effects of the 2-nitroimidazole Ro-07–0582 in primatesThe British Journal of Radiology, 1976
- Clinical testing of the radiosensitiser Ro-07-0582 III. Response of tumoursClinical Radiology, 1976
- Hydrated electrons and radiobiological sensitisationBiochemical and Biophysical Research Communications, 1963